Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in BioCryst Pharmaceuticals stock on July 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

BioCryst Pharmaceuticals Stock Down 9.0%

BioCryst Pharmaceuticals stock traded down $0.90 during midday trading on Tuesday, reaching $9.06. The company’s stock had a trading volume of 9,249,342 shares, compared to its average volume of 4,775,016. The business has a 50-day simple moving average of $9.75 and a 200-day simple moving average of $9.20. The company has a market cap of $2.32 billion, a P/E ratio of -6.04 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.15 earnings per share. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

BCRX has been the subject of several research analyst reports. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 29th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 27th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Cantor Fitzgerald raised their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $238,930,000. Vanguard Group Inc. grew its stake in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after acquiring an additional 482,494 shares during the period. RA Capital Management L.P. acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. raised its holdings in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after purchasing an additional 1,265,773 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.